American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 839-848 , November 2008

Left Ventricular Hypertrophy in Mild and Moderate Reduction in Kidney Function Determined Using Cardiac Magnetic Resonance Imaging and Cystatin C: The Multi-Ethnic Study of Atherosclerosis (MESA)

  • Andrew Moran, MD, MPH

      Affiliations

    • Division of General Internal Medicine, Department of Medicine, Columbia University, New York, NY
    • ,
  • Ronit Katz, DPhil

      Affiliations

    • Collaborative Health Studies Coordinating Center, University of Washington, Seattle, WA
    • ,
  • Nancy Swords Jenny, PhD

      Affiliations

    • Department of Pathology, University of Vermont, Colchester, VT
    • ,
  • Brad Astor, PhD, MPH

      Affiliations

    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
    • ,
  • David A. Bluemke, MD, PhD

      Affiliations

    • Department of Radiology, Johns Hopkins University, Baltimore, MD
    • ,
  • João A.C. Lima, MD

      Affiliations

    • Department of Cardiology, Johns Hopkins University, Baltimore, MD
    • ,
  • David Siscovick, MD, MPH

      Affiliations

    • Department of Epidemiology, University of Washington, Seattle, WA
    • ,
  • Alain G. Bertoni, MD

      Affiliations

    • Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC
    • ,
  • Michael G. Shlipak, MD, MPH

      Affiliations

    • Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC
    • General Internal Medicine Section, San Francisco Veterans Affairs Medical Center, San Francisco, CA
    • Corresponding Author InformationAddress correspondence to Michael G. Shlipak, MD, MPH, Chief, General Internal Medicine Section, VA Medical Center (111A1), 4150 Clement St, San Francisco, CA 94121

Received 7 February 2008 ,Accepted 4 June 2008.

References 

  1. Gardin JM, McClelland R, Kitzman D, et al. M-Mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol. 2001;87:1051–1057
  2. Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104:2039–2044
  3. Verdecchia P, Carini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI Study. J Am Coll Cardiol. 2001;38:1829–1835
  4. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK. Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol. 1997;29:641–647
  5. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32:1454–1459
  6. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–192
  7. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis. 2002;40:1202–1210
  8. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998;54:1720–1725
  9. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286–290
  10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  11. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA. 2005;293:1737–1745
  12. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16:1803–1810
  13. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
  14. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347–354
  15. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134
  16. Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005;67:217–226
  17. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320–327
  18. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens. 1995;8:221–228
  19. Cranney GB, Lotan CS, Dean L, Baxley W, Bouchard A, Pohost GM. Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging (Validation by calibrated ventricular angiography). Circulation. 1990;82:154–163
  20. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29–34
  21. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37:79–83
  22. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–2060
  23. Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45:268–271
  24. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142:497–505
  25. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–246
  26. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395–406
  27. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study Of Atherosclerosis: Objectives and design. Am J Epidemiol. 2002;156:871–881
  28. Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005;111:1313–1320
  29. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41:264–270
  30. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59:1–8
  31. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  32. Natori S, Lai S, Finn JP, et al. Cardiovascular function in Multi-Ethnic Study of Atherosclerosis: Normal values by age, sex, and ethnicity. AJR Am J Roentgenol. 2006;186(suppl 2):S357–S365
  33. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol. 1987;59:956–960
  34. Salton CJ, Chuang ML, O'Donnell CJ, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension (A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort). J Am Coll Cardiol. 2002;39:1055–1060
  35. Rosen BD, Edvardsen T, Lai S, et al. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: The Multi-Ethnic Study of Atherosclerosis. Circulation. 2005;112:984–991
  36. Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2007;50:412–420
  37. Rodondi N, Yerly P, Gabriel A, et al. Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults. Nephrol Dial Transplant. 2007;22:1107–1114
  38. Edvardsen T, Rosen BD, Pan L, et al. Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging—The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2006;151:109–114
  39. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003;41:11–17
  40. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002;162:1401–1408
  41. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504–510

 A list of author affiliations appears at the end of this article.

 Originally published online as doi:10.1053/j.ajkd.2008.06.012 on October 9, 2008.

 Trial registration: www.clinicaltrials.gov; study number: NCT00005487.

PII: S0272-6386(08)01094-9

doi: 10.1053/j.ajkd.2008.06.012

American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 839-848 , November 2008

Article Tools

* Image Usage & Resolution